Non-steroidal anti-inflammatory drugs (NSAIDs) are thought to reduce cancer risk by inhibiting cyclo-oxygenases, resulting in deceased formation of inflammatory mediators and oxidative stress. We examined whether the level of one oxidative stress marker, 15-F 2t -isoprostane, was affected by NSAID use in plasma and breast nipple aspirate fluids (NAF) of pre-menopausal women who were participating in a dietary intervention trial (n=121). Baseline levels of 15-F 2t -isoprostane were lower in NSAID users than non-users in both NAF and plasma, although the differences did not persist after intervention. Over the duration of the study, information on NSAID use was collected five times, and average 15-F 2t -isoprostane levels in both NAF and plasma exhibited a statistically significant trend for decreases with increased frequency of NSAID use. These results indicate that NSAID use can result in lower levels of 15-F 2t -isoprostane, which may have implications for the effects of NSAID use on breast cancer risk.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) use has been associated with decreased breast cancer risk in many but not all studies. A review of 14 studies in 2001 indicated that NSAID use might be associated with a relative risk for beast cancer of 0.82 [1] . Subsequent studies have either failed to find protective effects or in contrast have found protective effects that were dosedependent [2] [3] [4] [5] [6] [7] [8] . NSAIDS also have been suggested to be useful in treatment of breast cancer [9] , warranting further research on the effects of NSAIDS on the breast.
NSAIDs are thought to exert their cancer-preventive effects via inhibition of cyclo-oxygenase (COX) enzymes, but NSAIDs also can decrease formation of lipid peroxidation products. Several non-enzymatically formed arachidonate products were shown to be inhibitable by COX inhibitors in rats [10] . F 2 -isoprostanes are formed by non-enzymatic oxidation of arachidonylcontaining phospholipids, and they have been suggested to be a marker for the assessment of endogenous oxidative stress levels [11, 12] . In humans, 15-F 2t -isoprostane formation was shown to be decreased by COX-2 inhibitors, although to a more modest extent than other prostaglandins [13] [14] [15] . We previously reported that 15-F 2t -isoprostane are present in very high levels in breast nipple aspirate fluids (NAF) [16, 17] , and this may be important since lipid oxidation in the breast has been shown to be associated with breast cancer risk [18] [19] [20] . In this report, we therefore examined whether NSAID use was associated with decreased 15-F 2t -isoprostane levels in both NAF and plasma.
Methods
The study subjects were 121 healthy premenopausal (ages 21-50 years) non-smoking women with family history of breast cancer who participated in the Nutrition and Breast Health Study, a randomized intervention trial of low fat and high vegetable/fruits diets over a oneyear period [21] . The study was approved by the Human Investigation Committee of Wayne State University
In this study, fasting venous blood specimens were obtained at months 0, 3, 6 and 12 and NAF were collected at 0, 6 and 12 months as described [21, 22] . Approximately 60% of the participants were able to provide NAF specimens. At baseline and every 3 months thereafter (5 times over 12 months), dietary intake was assessed by four day food records, body weight was measured using a Health-o-Meter Professional Beam Scale, medication use, activity patterns and health in the 2-week period prior to the visit were recorded on a questionnaire. Average daily energy expenditure values in metabolic equivalents (MET) were then calculated based on subject body weight, time spent on each activity and published MET values for each activity [23] ). Total 15-F 2t -isoprostane levels in plasma were measured by a kit from Cayman Chemical Co. (Ann Arbor, MI) using a modified Sep-Pak procedure [22, 24] .
Analysis of covariance [25] was used to calculate and compare the covariate-adjusted mean 15-F 2t -isoprostane concentrations in plasma and NAF by NSAID use. To examine a potential dose-response relationship, we computed the number of visits at which NSIAD use was reported as an indicator for regularity or frequency of NSAID use during the study period. Then, covariateadjusted mean 15-F 2t -isoprostane concentrations in plasma and NAF were calculated according to the cumulative number of visits with NSAID use. In addition, multiple regression analysis was used to assess the linear relationship between plasma and NAF 15-F 2t -isopros-
2 ) were included as covariates in these analyses since they were major components of the intervention and since they were marginally associated with plasma and/or NAF 15-F 2t -isoprostane levels [24] . Age was not included because there were no associations within the limited age range of our study population. Plasma and NAF 15-F 2t -isoprostane concentrations as well as continuous independent variables were log-transformed (ln) before multivariate analysis.
Results and discussion
Users and non-users of NSAIDs did not differ significantly by age, body mass index, activity levels in METs, fat intake, supplement use, race, smoking history, or history of breast-feeding, except for the prevalence of respiratory allergies which was higher in single time users (p=0.009). In NSAID non-users, covariate adjusted mean levels of 15-F 2t -isoprostane tended to decrease with time on study in both plasma and NAF a Units are pg/ml for plasma 15-F 2t -isoprostane and pg/g for NAF 15-F 2t -isoprostane, adjusted for total fat intake/day, number of fruit and vegetable servings/day and body mass index. All variables in the model except NSAID use were log-transformed. b Standard error (SE). ( Table 1 ). Since 75% of the women were randomized to intervention diets, this suggests that intervention effects might be stronger in NSAID non-users. Levels in NSAID users were lower than that in NSAID users at baseline, and this was significant in NAF. At later time points, the 15-F 2t -isoprostane levels in NAF were very similar in NSAID users and non-users. This was partly due to 24 subjects who dropped out during intervention period. In plasma the lower levels in NSAID users persisted up to 6 months, indicating that levels in plasma do not necessarily predict levels in NAF ( Table 1) . The impact of frequency of NSAID use was examined over 12 months of study, and average 15-F 2t -isoprostane levels decreased with frequency of NSAID use reported at each of the five study visits ( Table 2 ). Levels were higher in both plasma and NAF for women who reported NSAID use at all five visits relative to women who reported NSAID use at four visits, but only four women used NSAIDs at all five visits. The trend for increasing occurrence of NSAID use and lower levels of 15-F 2t -isoprostane was statistically significant for both plasma and NAF ( Table 2 ). The decrease in NAF is especially noteworthy since the NAF composition may indicate what breast ductal cells are exposed to. These results indicate that NSAID use can result in lower levels of 15-F 2t -isoprostane in breast NAF, which may one mechanism by which NSAID use can decrease breast cancer risk.
